We've noticed that you're using an ad blocker Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
Progress and Future Directions Course Directors: Deepa S. Subramaniam, MD, MSc Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington, DC Giuseppe Giaccone, MD, PhD MedStar Georgetown Cancer Network Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital.
Frontiers People highlights some of the most notable researchers worldwide, widely recognized for their outstanding contributions in their different areas of expertise. In line with the Frontiers vision of spreading research knowledge across the world, the purpose of such a prestigious register is to promote an international forum for collaborations, research networking and peer reference.
While at Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C., Giuseppe Giaccone, MD, PhD, led a study looking at pembrolizumab in patients with recurrent thymic carcinoma.
Dr. Giuseppe Giaccone, MD, PhD is an internationally recognized expert in the field of lung cancer and developmental therapeutics. In January 2013 he joined the Lombardi Comprehensive Cancer Center at Georgetown University, Washington DC as the Associate Director for Clinical Research and the Director of Clinical Research for the MedStar Health Cancer Network’s Washington Region.
Medicine Grand Rounds Giuseppe Giaccone, M.D., Ph.D. Associate Director for Clinical Research. Sandra. Giuseppe Giaccone, MD, PhD. Subscribe Google Calendar iCal Outlook. Recent Activity. No recent activity. I'm Interested Invite Friends People Interested (3) Getting Here.
Giuseppe Giaccone, MD, PhD. Pembrolizumab (Keytruda) induced responses in more than one-fifth of patients with recurrent thymic carcinoma who had progressed following 1 or more lines of.
Gary K. Schwartz, MD, on melanoma studies Corey J. Langer, MD, on SRS and ipilimumab for malignant melanoma brain metastases Giuseppe Giaccone, MD, PhD, on ASCEND-1 trial.